NCT03553329View on ClinicalTrials.gov

Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

June 2, 2018

Primary Completion Date

June 2, 2018

Study Completion Date

June 2, 2018

Conditions
Unresecable Stage IIIc or IV Melanoma
Interventions
DRUG

dabrafenib

Monthly biological assessment which included: blood count, a blood electrolytes, an creatininemia, a dosage of urea, a dosage of transaminases, of gammaGT, of phosphatases alkaline, of LDH and of albumin.

Trial Locations (1)

86021

CHU DE Poitiers, Poitiers

All Listed Sponsors
lead

Poitiers University Hospital

OTHER

NCT03553329 - Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK | Biotech Hunter | Biotech Hunter